122 related articles for article (PubMed ID: 21845845)
1. [Development of a killed but metabolically active anthracis vaccine candidate strain].
Shen F; Yuan S; Zhan D; Wang Y; Ren M; Tao H; Wang P; Wang L; Chen D; Liu C
Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):781-9. PubMed ID: 21845845
[TBL] [Abstract][Full Text] [Related]
2. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.
Skoble J; Beaber JW; Gao Y; Lovchik JA; Sower LE; Liu W; Luckett W; Peterson JW; Calendar R; Portnoy DA; Lyons CR; Dubensky TW
Infect Immun; 2009 Apr; 77(4):1649-63. PubMed ID: 19168734
[TBL] [Abstract][Full Text] [Related]
3. Identification of the pXO1 plasmid in attenuated Bacillus anthracis vaccine strains.
Liang X; Zhang H; Zhang E; Wei J; Li W; Wang B; Dong S; Zhu J
Virulence; 2016 Jul; 7(5):578-86. PubMed ID: 27029580
[TBL] [Abstract][Full Text] [Related]
4. In vitro screen of bioinformatically selected Bacillus anthracis vaccine candidates by coupled transcription, translation, and immunoprecipitation analysis.
Gat O; Grosfeld H; Shafferman A
Methods Mol Biol; 2007; 375():211-33. PubMed ID: 17634604
[TBL] [Abstract][Full Text] [Related]
5. Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.
Gat O; Grosfeld H; Ariel N; Inbar I; Zaide G; Broder Y; Zvi A; Chitlaru T; Altboum Z; Stein D; Cohen S; Shafferman A
Infect Immun; 2006 Jul; 74(7):3987-4001. PubMed ID: 16790772
[TBL] [Abstract][Full Text] [Related]
6. Development of anthrax DNA vaccines.
Ferrari ME; Hermanson G; Rolland A
Curr Opin Mol Ther; 2004 Oct; 6(5):506-12. PubMed ID: 15537052
[TBL] [Abstract][Full Text] [Related]
7. [Anthrax: early steps of the intracellular stage of infection development].
Bakhteeva IV; Titareva GM; Kravchenko TB; Mironova RI; Noskov AN
Mol Gen Mikrobiol Virusol; 2005; (4):3-9. PubMed ID: 16334217
[TBL] [Abstract][Full Text] [Related]
8. [Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis].
Mikshis NI; Kudriavtseva OM; Bolothikova MF; Shulepov DV; Novikova LV; Popov IuA; Shchukovskaia TN; Drozdov IG; Kutyrev VV
Mol Gen Mikrobiol Virusol; 2007; (3):15-21. PubMed ID: 17886469
[TBL] [Abstract][Full Text] [Related]
9. [Progress on the vaccine for anthrax].
Zhan DW; Wang P; Wang LC; Zhang ZS
Wei Sheng Wu Xue Bao; 2005 Feb; 45(1):149-52. PubMed ID: 15847185
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a subunit vaccine against Bacillus anthracis.
Chichester JA; Musiychuk K; de la Rosa P; Horsey A; Stevenson N; Ugulava N; Rabindran S; Palmer GA; Mett V; Yusibov V
Vaccine; 2007 Apr; 25(16):3111-4. PubMed ID: 17280756
[TBL] [Abstract][Full Text] [Related]
11. [Construction of eag deletion mutant of Bacillus anthracis vaccine strain A16R].
Gao M; Liu X; Feng E; Tang H; Zhu L; Chen F; Wang H
Wei Sheng Wu Xue Bao; 2009 Jan; 49(1):23-31. PubMed ID: 19388260
[TBL] [Abstract][Full Text] [Related]
12. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.
Tournier JN; Ulrich RG; Quesnel-Hellmann A; Mohamadzadeh M; Stiles BG
Expert Rev Anti Infect Ther; 2009 Mar; 7(2):219-36. PubMed ID: 19254170
[TBL] [Abstract][Full Text] [Related]
13. Molecular study of genes involved in virulence regulatory pathways in Bacillus anthracis vaccine strain "Carbosap".
La Rosa G; Muscillo M; Sali M; De Carolis E; Marianelli C; Ciuchini F; Fasanella A; Adone R
New Microbiol; 2006 Oct; 29(4):307-10. PubMed ID: 17201098
[TBL] [Abstract][Full Text] [Related]
14. Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use.
Fasanella A; Tonello F; Garofolo G; Muraro L; Carattoli A; Adone R; Montecucco C
Vaccine; 2008 Oct; 26(45):5684-8. PubMed ID: 18775462
[TBL] [Abstract][Full Text] [Related]
15. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
[TBL] [Abstract][Full Text] [Related]
16. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization.
Herrmann JE; Wang S; Zhang C; Panchal RG; Bavari S; Lyons CR; Lovchik JA; Golding B; Shiloach J; Lu S
Vaccine; 2006 Jul; 24(31-32):5872-80. PubMed ID: 16790303
[TBL] [Abstract][Full Text] [Related]
17. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.
Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A
Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760
[TBL] [Abstract][Full Text] [Related]
18. Bacillus anthracis: interactions with the host and establishment of inhalational anthrax.
Passalacqua KD; Bergman NH
Future Microbiol; 2006 Dec; 1(4):397-415. PubMed ID: 17661631
[TBL] [Abstract][Full Text] [Related]
19. Progress and novel strategies in vaccine development and treatment of anthrax.
Chitlaru T; Altboum Z; Reuveny S; Shafferman A
Immunol Rev; 2011 Jan; 239(1):221-36. PubMed ID: 21198675
[TBL] [Abstract][Full Text] [Related]
20. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
